Clinical trialsCompany release

Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned

Optimi Health Corp. (OPTH) · Wed 18 Nov 2026

The Canadian company has asked Health Canada to amend its OPTI-101 protocol and expects to start an MDMA-assisted therapy Phase 3 in PTSD in 2027.

Optimi Health Corp. said on 18 November 2026 that it has asked Health Canada to approve a protocol amendment to its open-label psilocybin study, OPTI-101, in severe major depressive disorder. The change would convert the study into a randomised, double-blind Phase 2b trial in 200 adults.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Optimi Health Corp. ↗

Article written by VigiEye from the official source (Optimi Health Corp.). Claims are the company's own. AI-assisted; check the source before acting.